Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 9/20 | 0.60 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GOT1 | P17174 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497434 | 0.88 | PIM3 (0.55) | NR4A2PIM3PIM1NUDT1CREBBP | |
| SCHEMBL12565533 | 0.87 | NR4A2 (0.49) | NR4A2PIM3PIM1NUDT1CREBBP | |
| SCHEMBL2588280 | 0.82 | PIM3 (0.50) | NR4A2PIM3PIM1CREBBPKDM4E | |
| SCHEMBL22587514 | 0.82 | PIM3 (0.50) | NR4A2PIM3PIM1NUDT1CREBBP | |
| SCHEMBL6315440 | 0.82 | NR4A2 (0.61) | NR4A2PIM3PIM1NUDT1CREBBP | |
| SCHEMBL31480354 | 0.82 | PIM3 (0.50) | NR4A2PIM3PIM1NUDT1CREBBP | |
| SCHEMBL14774594 | 0.82 | PIM3 (0.50) | NR4A2PIM3PIM1NUDT1CREBBP | |
| SCHEMBL2595142 | 0.81 | AURKA (0.46) | NR4A2BRPF1KDM4EGOT1P2RX7 | |
| SCHEMBL38662412 | 0.80 | PIM3 (0.45) | NR4A2PIM3PIM1CREBBPKDM4E | |
| SCHEMBL16340090 | 0.79 | PIM3 (0.50) | NR4A2PIM3PIM1CREBBPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724052-B | GPR101 protein receptor inhibitor and preparation and application thereof | 南京艾美斐生物医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-112724052-A | GPR101 protein receptor inhibitor and preparation and application thereof | 南京艾美斐生物医药科技有限公司 | 2021-04-30 | — | — | CN | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2566327-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | NR4A2 1964/4885PIM3 733/4885PIM1 590/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | NR4A2 2018/4885PIM3 847/4885PIM1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.